,
,
,
,
,
,
,
,
,
,
,
, 60 6.3.2.2 PATIENT GLOBAL IMPRESSION -SEVERITY (PGI-S) AND PATIENT GLOBAL IMPRESSION-CHANGE (PGI-C), p.61
, , p.61
,
,
,
,
,
,
,
,
,
,
,
, CLINICAL LABORATORY ABNORMALITIES AND OTHER ABNORMAL ASSESSMENTS AS ADVERSE EVENTS
,
,
,
Crohn's disease. s.l. : Lancet, vol.380, pp.1590-605, 2012. ,
, ALD n° 24 -Guide médecin sur la Maladie de Cohn et de la Rectocolite hémorragique. s.l. : Système national d'information inter-régimes de l'Assurance maladie (SNIIRAM) , Cartographie des patients et des dépenses, 2008.
Increasing incidenceand prevalence of the inflammatory bowel diseases with time, based on systematic review. s.l. : Gastroenterology, vol.142, pp.46-54, 2012. ,
Understanding and preventing the global incidence of Inflammatory Bowel Diseases. s.l. : Gastroenterology, vol.152, pp.313-321, 2017. ,
Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. s.l. : Pharmacology & Therapeutics, vol.159, pp.110-119, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01664661
Determinants of health-related quality of life in Crohn's disease: a systematic review and metaanalysis. s.l, J Crohns Colitis, vol.8, pp.93-106, 2014. ,
Smoking in inflammatory bowel disease : impact on disease course and insights into the aetiology of its effect. s.l, J Crohns Colitis, vol.8, pp.717-742, 2014. ,
Evidence that stress contributes to inflammatory bowel disease: evalutaion, synthesis and future direction. s.l. : Inflamm Bowel Dis, vol.11, pp.600-608, 2005. ,
Stressful life events as risk factor for inflammatory bowel disease onset: a population-based case-control study. s.l, Am J Gastroenterol, vol.102, pp.122-153, 2007. ,
Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. s.l, Scand J Gastroenterol, vol.53, pp.379-389, 2018. ,
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. s.l. : Journal of Crohn's & colitis, vol.4, pp.28-62, 2010. ,
, Management strategies to improve outcomes in patients with Inflammatory Bowel diseases. s.l. : Gastroenterology, vol.152, pp.351-361, 2017.
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. s.l. : Gastroenterology, vol.141, pp.1194-1201, 2011. ,
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. s.l. : Gastroenterology, vol.138, pp.463-471, 2010. ,
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. s.l. : Lancet, vol.371, pp.660-667, 2008. ,
Optimizing anti-TNF-a therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. s.l. : Clinical Gastroenterology and Hepatology, vol.14, pp.550-55, 2016. ,
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials, Expert Opinion on Investigational Drugs. s.l. : Expert Opinion on Investigational Drugs, vol.27, pp.595-599, 2019. ,
Anti -interleukin-12 and anti-interleukin-23 agents in Crohn's disease. s.l. : Expert Opinion on Biological Therapy, vol.19, pp.89-98, 2019. ,
Neutralization of soluble and membrane tumor necrosis factor (TNF) by infliximab, adalimumab, or certolizumab pegol using p55 or p75 TNF-receptorspecific bioassays. s.l. : Gastroenterology, vol.130, p.697, 2006. ,
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. s.l. : Gastroenterology, vol.132, pp.52-65, 2007. ,
, Switching between Biologics and Biosimilars in Inflammatory Bowel Disease. s.l. : Clinical Gastroenterology and Hepatology, vol.17, pp.818-823, 2019.
evelopment of biosimilars. s.l. : Semin Arthritis Rheum, vol.45, pp.11-19, 2016. ,
, Expert Committee on Biological. Guidelines on evaluation of similar biotherapeutic products, 2009.
Biosimilars: in support of extrapolation of indications. s.l, J Crohns Colitis, vol.8, issue.5, pp.431-436, 2014. ,
Biosimilars: the science of extrapolation. s.l. : Blood, vol.124, pp.3191-3197, 2014. ,
Developing oncology biosimilars: an essential approach for the future. s.l, J Semin Oncol, vol.1, issue.40, pp.5-24, 2013. ,
ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. s.l. : J Crohn's Colitis, vol.11, pp.26-34, 2017. ,
Switching from originatorinfliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. s.l. : Lancet, vol.389, pp.2304-2316, 2017. ,
Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. s.l. : Inflamm Bowel Dis, vol.19, pp.2199-206, 2013. ,
Medication non-adherence is associated with increased medical health care costs. s.l. : Dig Dis Sci, vol.53, pp.1020-1024, 2008. ,
Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. s.l. : Adv Ther, vol.26, pp.936-982, 2009. ,
Adherence to infliximab therapy in inflammatory bowel disease patients in real-life setting. s.l, J Dig Dis, vol.10, pp.556-573, 2017. ,
Non-pharmacologicol effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. s.l. : BioGrugs, vol.32, pp.397-404, 2018. ,
To see or NOsee: the debate on the nocebo effect and optimizing the use of biosimilars. s.l, Adv Ther, vol.35, pp.749-753 ,
The nocebo effect: a clinical challenge in the era of biosimilars. s.l. : Expert Rev Clin Immunol, vol.14, pp.739-749, 2018. ,
Efficacy and safety results of a phase III study comparing FKB327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis. s.l. : Ann Rheum Dis, vol.76, p.59, 2017. ,
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, doubleblind, phase III equivalence study. s.l. : Ann Rheum Dis, vol.76, pp.1679-1687, 2017. ,
A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. s.l, Am J Gastroenterol, vol.00, pp.1-10 ,
Inflammatory Bowel disease: toward a personalized medicine. s.l. : Ther Adv Gastroenterol, vol.11, pp.1-15, 2018. ,
Biosimilars of adalimumab: the upcoming challenge in IBD. s.l. : Expert Opin Biol Ther, 2019. ,
Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab. s.l. : BioDrugs, vol.30, pp.321-338, 2016. ,
Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transititransition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. s.l, Br J Dermatol, vol.177, pp.1562-1574, 2017. ,
A randomized phase I comparativepharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. s.l, J Clin Pharm Ther, vol.42, issue.6, pp.672-678, 2017. ,
Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. s.l. : Arthritis Rheumatol, vol.70, pp.40-48, 2018. ,
Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. s.l. : Arthritis Rheumatol, vol.70, pp.832-840, 2018. ,
an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. s.l. : Expert Opin Biol Ther, pp.1-9, 2017. ,
Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. s.l, Br J Dermatol, vol.179, issue.3, pp.623-631, 2018. ,
, FKB327: An Adalimumab Biosimilar. s.l. : BioDrugs, 2019, pp.113-116
Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subject. s.l. : Br, J Clin Pharmacol, vol.83, pp.1405-1415, 2017. ,
The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases. s.l. : Expert Opin Biol Ther, 2019. ,
Anti-TNF biosimilars in Crohn's disease: a patient-centric interdisciplinary approach. s.l. : Expert Rev Gastroenterol Hepatol, vol.13, pp.731-738, 2019. ,
Nocebo effects, patient-clinician communication, and therapeutic outcomes, JAMA, vol.307, pp.567-568, 2012. ,
Open-label nonmandatory transitioning from originator etanercept to biosimilar SB4: 6-month results from a controlled cohort study. s.l. : Arthritis Rheumatol, vol.70, pp.60-68, 2018. ,
Higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy. s.l. : Ann Rheum Dis, vol.76, p.557, 2017. ,
Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. s.l. : Arthritis Rheumatol, vol.70, pp.60-68, 2018. ,
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patient. s.l. : Aliment Pharmacol Ther, vol.49, pp.1181-1187, 2019. ,
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. s.l. : Aliment Pharmacol Ther, vol.47, pp.356-363, 2018. ,
The nocebo effect challenges the non-medical infliximab switch in practice. s.l, Eur J Clin Pharmacol, vol.74, pp.655-661, 2018. ,
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. s.l, Am J Gastroenterol, vol.110, pp.1324-1362, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01191653
,
, European Crohn's and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology
Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complicat. s.l, J Crohns Colitis, vol.13, pp.144-164, 2019. ,
The nocebo effect: patient expectations and medication side effects. s.l, Postgrad Med J, vol.89, pp.540-546, 2013. ,
Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. s.l, J Psychosom Res, vol.47, issue.6, pp.555-67, 1999. ,
Adalimumab in ulcerative colitis-efficacy, safety and optimization in the era of treat-to target, vol.5, pp.613-621, 2017. ,
,
, European Crohn's and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology
Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. s.l, J Crohns Colitis, vol.13, issue.3, pp.273-284, 2019. ,
Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q). s.l. : Value Health, vol.11, pp.913-939, 2008. ,
, Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. s.l. : Inflamm Bowel Dis, vol.23, pp.333-340, 2017.
Medication adherence in inflammatory bowel disease. s.l. : Intest Res, vol.15, pp.434-445, 2017. ,
Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases. s.l. : PLoS One, vol.8, p.56247, 2013. ,
Influence of intention to adhere, beliefs and satisfaction about medicines on adherence in solid organ transplant recipients. s.l. : Transplantation, vol.98, pp.222-230, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02007518